There are currently 87 clinical trials in Wilmington, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including PMG Research of Wilmington, LLC, GSK Investigational Site, PMG Research of Wilmington and New Hanover Regional Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717
Recruiting
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiatio... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Novant Health Cancer Institute Radiation Oncology - Wilmington, Wilmington, North Carolina +1 locations
Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
Project Talk Trial: Engaging Underserved Communities in End-of-life Conversations
NCT04612738
Recruiting
Compared to the general population, individuals from underserved communities are more likely to receive low quality end-of-life care and unwanted, costly and burdensome treatments due in part to a lack of advance care planning (ACP; the process of discussing wishes for end-of-life care with loved ones/clinicians and documenting them in advance directives). This study will use existing, trusted, and respected social networks to evaluate two conversation-based tools intended to engage underserved... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Plaza on Princess, Wilmington, North Carolina
Conditions: Advance Care Planning, Advance Directives, Terminal Illness, Chronic Illness, Communication
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/05/2025
Locations: Accellacare US Inc. of Wilmington, Wilmington, North Carolina
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/05/2025
Locations: Accellacare US Inc. of Wilmington, Wilmington, North Carolina
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
NCT03911700
Recruiting
This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: New Hanover Regional Medical Center, Wilmington, North Carolina
Conditions: Open Midline Laparotomy
Register for Updates
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME
NCT04108156
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W). The substudy will evaluate safety of re-implanting the updated PDS with ranibizumab and the refill-exchange procedures following re-implantation in participants with DME who were previously enrolled in the main Study, GR40550. Up to 100 participants from the main study will b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Cape Fear Retinal Associates, Wilmington, North Carolina
Conditions: Diabetic Macular Edema
Register for Updates
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064
Recruiting
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/01/2025
Locations: Cape Fear Retinal Associates, PC, Wilmington, North Carolina
Conditions: Wet Age Related Macular Degeneration, wAMD
Register for Updates
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
NCT06496620
Recruiting
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
05/01/2025
Locations: Research Site 006, Wilmington, North Carolina
Conditions: COPD
Register for Updates
A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries
NCT06887959
Recruiting
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of SUZ for acute pain after laparoscopic procedures of the intraperitoneal or retroperitoneal cavities or arthroscopic orthopedic procedures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Seaside Clinical Research Institute, Wilmington, North Carolina
Conditions: Acute Pain
Register for Updates
Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
NCT06258902
Recruiting
The participants of this study will be of any age who are exposed to at least 1 dose of odevixibat at any time during pregnancy (from 1 day prior to conception to pregnancy outcome) and/or at any time during lactation (up to 12 months of infant age or weaning, whichever comes first. This study will collect data obtained via a variety of sources, including enrolled pregnant or lactating participants, the healthcare providers (HCP) involved in their care or the care of their infants, if applicabl... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
04/30/2025
Locations: Virtual Research Coordination Center Odevixibat (BYLVAY) Pregnancy Surveillance Program, Wilmington, North Carolina
Conditions: Pregnancy Related
Register for Updates
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
NCT06143514
Recruiting
The primary objective of the lactation study is to characterize the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who receive BRIUMVI™ therapeutically for the treatment of relapsing forms of multiple sclerosis (RMS).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: PROVIDE Virtual Research Coordination Center, Wilmington, North Carolina
Conditions: Relapsing Multiple Sclerosis
Register for Updates
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
NCT06433765
Recruiting
The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.
Gender:
FEMALE
Ages:
Between 15 years and 50 years
Trial Updated:
04/28/2025
Locations: BRIUMVI® Pregnancy Registry Virtual Research Coordination Center, Wilmington, North Carolina
Conditions: Multiple Sclerosis
Register for Updates